Investor Relations

Thank you for checking on Entheon. We are glad to have you here!

Request Investor Presentation

"Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada."

- Timothy Ko, CEO

Press Releases

Official publications released at Newsfile Corp.

February 24, 2022

Entheon Biomedical Announces EBIQ-101 First-Patient Dose

February 16, 2022

Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study

February 3, 2022

Entheon Biomedical Announces the Approval of DMT Clinical Trial

January 18, 2022

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

January 18, 2022

Entheon Biomedical Corp. Files Preliminary Shelf Prospectus

January 6, 2022

Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee

Previous Releases

Stock information

CSE:ENBI

OTC:ENTBF

FSE:1XU1

share structure

Financial statements

August 31, 2021

Q3 2021 Condensed Consolidated Interim Financial Statements

August 31, 2021

Q3 2021 Management’s Discussion and Analysis

May 31, 2021

Q2 2021 Condensed Consolidated Interim Financial Statements

Previous Statements

Get in touch

Please enter your information to receive our investor package or reach out to us directly using the information below.

Joseph Cullen
Investor Relations

ir@entheonbiomedical.com
+1 (778) 919-8615

Please remember our office hours are in Pacific Time (GMT-8, Vancouver - BC, Canada)
By submitting this form you agree to receive communications from Entheon Biomedical. We commit to never selling your data and to keep your information safe. Read our Privacy Policy.
Thank you!
We will get in touch soon.
Oops! Something went wrong while submitting the form.